GlassScriptPhysician profile
Olivia M Orteza
NPI 1316395569
$6,475.37
in general payments reported to CMS, 2019-2025
27 companies · $827 in 2025
The $827 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $281 · 2021: $440 · 2022: $1,699 · 2023: $742 · 2024: $1,260 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $646.12 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $624.02 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $562.44 | 2022-2024 | Lokelma, Farxiga |
| Amgen INC. | $540.02 | 2022-2025 | Tavneos, Krystexxa |
| Novo Nordisk INC | $399.23 | 2019 | |
| Ardelyx, INC. | $348.61 | 2024-2025 | Xphozah 30 Mg |
| Alexion Pharmaceuticals, INC. | $345.24 | 2022-2024 | |
| Travere Therapeutics, INC. | $326.06 | 2023-2025 | Filspari |
| Horizon Therapeutics Plc | $283.61 | 2020-2023 | Krystexxa |
| Vifor Pharma, INC. | $264.31 | 2021-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $252.06 | 2021-2023 | Korsuva |
| Janssen Pharmaceuticals, INC | $244.33 | 2019 | |
| Mylan Specialty L.P. | $168.22 | 2019 | |
| Calliditas Therapeutics US INC. | $162.68 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $154.06 | 2019-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $150.76 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $149.72 | 2024 | Terlivaz |
| Apellis Pharmaceuticals, INC. | $122.31 | 2025 | Empaveli |
| Sunovion Pharmaceuticals INC. | $120.21 | 2020 | |
| Abbvie INC. | $113.97 | 2019 | |
| Amarin Pharma, INC. | $110.61 | 2019 | |
| Nxstage Medical, INC. | $91.73 | 2025 | Nxstage System One |
| Ucb, INC. | $89.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.03 | 2025 | Jardiance |
| Pfizer INC. | $42.47 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Orteza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.